Johnson & Johnson (JNJ) 98.96 $JNJ
Johnson & Johnson's Earnings Made Easy
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - 1 hr 34 mins ago
Johnson & Johnson 's recently reported earnings and the massive health-care conglomerate posted another strong performance. Revenue grew 3% and earnings popped 8%, beating analysts' expectations. But is there trouble lurking beneath the rosy...
Johnson & Johnson's Headache-Fixing Earnings, Mattel's Un-Fun Earnings, and Why Stocks Popped All We
Jack Kramer and Nick Martell, The Motley Fool - Motley Fool - Sat Apr 19, 6:00PM CDT
Time to take a break from stuffing your face with Cadbury Creme Eggs. Although the stock market was closed for Good Friday, the S&P 500 rose all four days during the holiday-shortened week, which was chock-full of earnings reports. 1. Stock...
Why Medtronic Is One of the Smartest Companies on the Planet
Leo Sun, The Motley Fool - Motley Fool - Sat Apr 19, 9:00AM CDT
MIT Tech Review recently named Medtronic one of of the 50 smartest companies of 2013, placing the 65-year-old medical device company side by side with much younger companies like Google , and...
Can the Dow Climb Higher on Consumer Strength? Earnings Say Yes
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 18, 7:02PM CDT
The Dow Jones Industrials had a strong week, rising more than 2% as earnings season kicked into full gear. Yet, even as nine different Dow components reported earnings during the week, consumer-facing stocks Coca-Cola and Johnson & Johnson...
How Big Is the Threat to This Johnson & Johnson Blockbuster?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
Johnson & Johnson has been one of the most successful big drug companies over the past three years. Despite an industry-wide sales drag caused by patent expiration on top-selling drugs, Johnson has skirted the headwind thanks to a wave of...
Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.
Earnings Roundup: St. Jude's 1 Bright Spot
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
St. Jude 's tepid first-quarter results mask a quickening in sales for the company's atrial fibrillation products that shouldn't be ignored by investors. St. Jude has been boosting its atrial fibrillation, or AF, offering in anticipation of...
Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
Investors focusing on Johnson and Johnson 's 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed. However, tepid results in the company's medical device and consumer goods business mask much stronger growth in...
Final Glance: Medical Devices companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
This Week's 5 Smartest Stock Moves
Rick Munarriz, The Motley Fool - Motley Fool - Thu Apr 17, 4:15PM CDT
If you're feeling good about the market, you're not alone. Take my hand as we go over some of this week's more uplifting headlines. 1. Netflix cracks the whip Netflix started a neat practice last year, publishing the monthly average speeds...
Johnson & Johnson's 3 Major Strengths
Peter Stephens, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
I recently wrote a mini-series on Johnson & Johnson , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices. Now seems like an opportune moment to check out the strengths of J&J as a group, with...
AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
Early Glance: Pharmaceuticals companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Dow 30 Stock Roundup: JNJ Beats, JPM Disappoints - Analyst Blog
Swarup Gupta - Zacks Investment Research - Thu Apr 17, 9:46AM CDT
The Dow notched up substantial gains during a holiday shortened week, boosted by several positive factors.
New Recycling Study Shows Lack Of Bins Is No. 1 Barrier To Recycling In The Home
PR Newswire - Thu Apr 17, 9:14AM CDT
Nearly three-quarters (72%) of consumers consistently recycle in the home, but despite a genuine concern for the environment, only about half do so in rooms beyond the kitchen. According to the 2014 Cone Communications Recycling in the Home Survey, in partnership with the Johnson & Johnson Family of Consumer Companies as part of its Care To Recycle program, there are several key barriers to expanding recycling in the home, including the lack of room-specific recycling bins and clear product labeling.
What Do General Electric and Chipotle Earnings Mean?: StockTwits
at The Street - Thu Apr 17, 8:46AM CDT
This has been a huge week for earnings. Here's a quick review of today's Chipotle and General Electric earnings reports.
High Hopes for Ketamine Depression Treatments
at The Street - Thu Apr 17, 8:45AM CDT
Does a recreational drug and horse tranquilizer really have potential as an effective treatment for one of the toughest, and most common, psychiatric illnesses out there?
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
Johnson & Johnson's Earnings Made Easy
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - 1 hr 34 mins ago
Johnson & Johnson 's recently reported earnings and the massive health-care conglomerate posted another strong performance. Revenue grew 3% and earnings popped 8%, beating analysts' expectations. But is there trouble lurking beneath the rosy...
Johnson & Johnson's Headache-Fixing Earnings, Mattel's Un-Fun Earnings, and Why Stocks Popped All We
Jack Kramer and Nick Martell, The Motley Fool - Motley Fool - Sat Apr 19, 6:00PM CDT
Time to take a break from stuffing your face with Cadbury Creme Eggs. Although the stock market was closed for Good Friday, the S&P 500 rose all four days during the holiday-shortened week, which was chock-full of earnings reports. 1. Stock...
Why Medtronic Is One of the Smartest Companies on the Planet
Leo Sun, The Motley Fool - Motley Fool - Sat Apr 19, 9:00AM CDT
MIT Tech Review recently named Medtronic one of of the 50 smartest companies of 2013, placing the 65-year-old medical device company side by side with much younger companies like Google , and...
Can the Dow Climb Higher on Consumer Strength? Earnings Say Yes
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 18, 7:02PM CDT
The Dow Jones Industrials had a strong week, rising more than 2% as earnings season kicked into full gear. Yet, even as nine different Dow components reported earnings during the week, consumer-facing stocks Coca-Cola and Johnson & Johnson...
How Big Is the Threat to This Johnson & Johnson Blockbuster?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
Johnson & Johnson has been one of the most successful big drug companies over the past three years. Despite an industry-wide sales drag caused by patent expiration on top-selling drugs, Johnson has skirted the headwind thanks to a wave of...
Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.
Earnings Roundup: St. Jude's 1 Bright Spot
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
St. Jude 's tepid first-quarter results mask a quickening in sales for the company's atrial fibrillation products that shouldn't be ignored by investors. St. Jude has been boosting its atrial fibrillation, or AF, offering in anticipation of...
Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
Investors focusing on Johnson and Johnson 's 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed. However, tepid results in the company's medical device and consumer goods business mask much stronger growth in...
Final Glance: Medical Devices companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
This Week's 5 Smartest Stock Moves
Rick Munarriz, The Motley Fool - Motley Fool - Thu Apr 17, 4:15PM CDT
If you're feeling good about the market, you're not alone. Take my hand as we go over some of this week's more uplifting headlines. 1. Netflix cracks the whip Netflix started a neat practice last year, publishing the monthly average speeds...
Johnson & Johnson's 3 Major Strengths
Peter Stephens, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
I recently wrote a mini-series on Johnson & Johnson , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices. Now seems like an opportune moment to check out the strengths of J&J as a group, with...
AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
Early Glance: Pharmaceuticals companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Dow 30 Stock Roundup: JNJ Beats, JPM Disappoints - Analyst Blog
Swarup Gupta - Zacks Investment Research - Thu Apr 17, 9:46AM CDT
The Dow notched up substantial gains during a holiday shortened week, boosted by several positive factors.
New Recycling Study Shows Lack Of Bins Is No. 1 Barrier To Recycling In The Home
PR Newswire - Thu Apr 17, 9:14AM CDT
Nearly three-quarters (72%) of consumers consistently recycle in the home, but despite a genuine concern for the environment, only about half do so in rooms beyond the kitchen. According to the 2014 Cone Communications Recycling in the Home Survey, in partnership with the Johnson & Johnson Family of Consumer Companies as part of its Care To Recycle program, there are several key barriers to expanding recycling in the home, including the lack of room-specific recycling bins and clear product labeling.
What Do General Electric and Chipotle Earnings Mean?: StockTwits
at The Street - Thu Apr 17, 8:46AM CDT
This has been a huge week for earnings. Here's a quick review of today's Chipotle and General Electric earnings reports.
High Hopes for Ketamine Depression Treatments
at The Street - Thu Apr 17, 8:45AM CDT
Does a recreational drug and horse tranquilizer really have potential as an effective treatment for one of the toughest, and most common, psychiatric illnesses out there?
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
